Chapter 1. Research Scope & Methodology
1.1 Market Definition
1.2 Analysis Period & Currency
1.3 Segmentation
1.3.1 Agentic AI In Pharmaceuticals Market, by End User
1.3.2 Agentic AI In Pharmaceuticals Market, by Deployment Mode
1.3.3 Agentic AI In Pharmaceuticals Market, by Application
1.3.4 Agentic AI In Pharmaceuticals Market, by Geography
1.4 Research Methodology
Chapter 2. Market Overview
2.1 COVID-19 Impact
2.2 Market Composition and Scenario
Chapter 3. Key Factors Impacting Market
3.1 Market Drivers
3.2 Market Restraints
3.3 Market Opportunities
3.4 Market Challenges
3.5 Market Trends
3.6 State of Competition
3.7 Market Consolidation
3.8 Key Customer Criteria
Chapter 4. Product Life Cycle
Chapter 5. Value Chain Analysis of Agentic AI In Pharmaceuticals Market
Chapter 6. Competition Analysis - Global
6.1 Market Share Analysis
6.2 Recent Developments and Strategies
6.2.1 Mergers & Acquisitions
6.2.2 Product Launch & Product Expansion
6.2.3 Partnership, Collaboration & Agreements
6.2.4 Geographical Expansion
Chapter 7. Segmentation By End User
7.1 Large Pharmaceutical Companies
7.2 Small and Mid-Size Biotech Firms
7.3 Contract Research Organizations
7.4 Academic and Research Institutes
Chapter 8. Segmentation By Deployment Mode
8.1 Cloud-Based
8.2 Hybrid
8.3 On-Premise
Chapter 9. Segmentation By Application
9.1 Clinical-Trial Design and Recruitment
9.2 Drug Discovery and Lead Identification
9.3 Lead Optimization
9.4 Pharmacovigilance and Safety Monitoring
9.5 Pre-clinical Development
9.6 Manufacturing-Process Optimization
9.7 Other Application
Chapter 10. North America Market
10.1 Market Overview
10.2 Key Factors Impacting Market
10.2.1 Market Drivers
10.2.2 Market Restraints
10.2.3 Market Opportunities
10.2.4 Market Challenges
10.2.5 Market Trends
10.2.6 State of Competition
10.2.7 Market Consolidation
10.2.8 Key Customer Criteria
10.3 Product Life Cycle
10.4 Segmentation By End User
10.4.1 Large Pharmaceutical Companies
10.4.2 Small and Mid-Size Biotech Firms
10.4.3 Contract Research Organizations
10.4.4 Academic and Research Institutes
10.5 Segmentation By Deployment Mode
10.5.1 Cloud-Based
10.5.2 Hybrid
10.5.3 On-Premise
10.6 Segmentation By Application
10.6.1 Clinical-Trial Design and Recruitment
10.6.2 Drug Discovery and Lead Identification
10.6.3 Lead Optimization
10.6.4 Pharmacovigilance and Safety Monitoring
10.6.5 Pre-clinical Development
10.6.6 Manufacturing-Process Optimization
10.6.7 Other Application
10.7 Segmentation By Country
10.7.1 US
10.7.1.1 Segmentation By End User
10.7.1.1.1 Large Pharmaceutical Companies
10.7.1.1.2 Small and Mid-Size Biotech Firms
10.7.1.1.3 Contract Research Organizations
10.7.1.1.4 Academic and Research Institutes
10.7.1.2 Segmentation By Deployment Mode
10.7.1.2.1 Cloud-Based
10.7.1.2.2 Hybrid
10.7.1.2.3 On-Premise
10.7.1.3 Segmentation By Application
10.7.1.3.1 Clinical-Trial Design and Recruitment
10.7.1.3.2 Drug Discovery and Lead Identification
10.7.1.3.3 Lead Optimization
10.7.1.3.4 Pharmacovigilance and Safety Monitoring
10.7.1.3.5 Pre-clinical Development
10.7.1.3.6 Manufacturing-Process Optimization
10.7.1.3.7 Other Application
10.7.2 Canada
10.7.2.1 Segmentation By End User
10.7.2.1.1 Large Pharmaceutical Companies
10.7.2.1.2 Small and Mid-Size Biotech Firms
10.7.2.1.3 Contract Research Organizations
10.7.2.1.4 Academic and Research Institutes
10.7.2.2 Segmentation By Deployment Mode
10.7.2.2.1 Cloud-Based
10.7.2.2.2 Hybrid
10.7.2.2.3 On-Premise
10.7.2.3 Segmentation By Application
10.7.2.3.1 Clinical-Trial Design and Recruitment
10.7.2.3.2 Drug Discovery and Lead Identification
10.7.2.3.3 Lead Optimization
10.7.2.3.4 Pharmacovigilance and Safety Monitoring
10.7.2.3.5 Pre-clinical Development
10.7.2.3.6 Manufacturing-Process Optimization
10.7.2.3.7 Other Application
10.7.3 Mexico
10.7.3.1 Segmentation By End User
10.7.3.1.1 Large Pharmaceutical Companies
10.7.3.1.2 Small and Mid-Size Biotech Firms
10.7.3.1.3 Contract Research Organizations
10.7.3.1.4 Academic and Research Institutes
10.7.3.2 Segmentation By Deployment Mode
10.7.3.2.1 Cloud-Based
10.7.3.2.2 Hybrid
10.7.3.2.3 On-Premise
10.7.3.3 Segmentation By Application
10.7.3.3.1 Clinical-Trial Design and Recruitment
10.7.3.3.2 Drug Discovery and Lead Identification
10.7.3.3.3 Lead Optimization
10.7.3.3.4 Pharmacovigilance and Safety Monitoring
10.7.3.3.5 Pre-clinical Development
10.7.3.3.6 Manufacturing-Process Optimization
10.7.3.3.7 Other Application
10.7.4 Rest of North America
10.7.4.1 Segmentation By End User
10.7.4.1.1 Large Pharmaceutical Companies
10.7.4.1.2 Small and Mid-Size Biotech Firms
10.7.4.1.3 Contract Research Organizations
10.7.4.1.4 Academic and Research Institutes
10.7.4.2 Segmentation By Deployment Mode
10.7.4.2.1 Cloud-Based
10.7.4.2.2 Hybrid
10.7.4.2.3 On-Premise
10.7.4.3 Segmentation By Application
10.7.4.3.1 Clinical-Trial Design and Recruitment
10.7.4.3.2 Drug Discovery and Lead Identification
10.7.4.3.3 Lead Optimization
10.7.4.3.4 Pharmacovigilance and Safety Monitoring
10.7.4.3.5 Pre-clinical Development
10.7.4.3.6 Manufacturing-Process Optimization
10.7.4.3.7 Other Application
Chapter 11. Europe Market
11.1 Market Overview
11.2 Key Factors Impacting Market
11.2.1 Market Drivers
11.2.2 Market Restraints
11.2.3 Market Opportunities
11.2.4 Market Challenges
11.2.5 Market Trends
11.2.6 State of Competition
11.2.7 Market Consolidation
11.2.8 Key Customer Criteria
11.3 Product Life Cycle
11.4 Segmentation By End User
11.4.1 Large Pharmaceutical Companies
11.4.2 Small and Mid-Size Biotech Firms
11.4.3 Contract Research Organizations
11.4.4 Academic and Research Institutes
11.5 Segmentation By Deployment Mode
11.5.1 Cloud-Based
11.5.2 Hybrid
11.5.3 On-Premise
11.6 Segmentation By Application
11.6.1 Clinical-Trial Design and Recruitment
11.6.2 Drug Discovery and Lead Identification
11.6.3 Lead Optimization
11.6.4 Pharmacovigilance and Safety Monitoring
11.6.5 Pre-clinical Development
11.6.6 Manufacturing-Process Optimization
11.6.7 Other Application
11.7 Segmentation By Country
11.7.1 Germany
11.7.1.1 Segmentation By End User
11.7.1.1.1 Large Pharmaceutical Companies
11.7.1.1.2 Small and Mid-Size Biotech Firms
11.7.1.1.3 Contract Research Organizations
11.7.1.1.4 Academic and Research Institutes
11.7.1.2 Segmentation By Deployment Mode
11.7.1.2.1 Cloud-Based
11.7.1.2.2 Hybrid
11.7.1.2.3 On-Premise
11.7.1.3 Segmentation By Application
11.7.1.3.1 Clinical-Trial Design and Recruitment
11.7.1.3.2 Drug Discovery and Lead Identification
11.7.1.3.3 Lead Optimization
11.7.1.3.4 Pharmacovigilance and Safety Monitoring
11.7.1.3.5 Pre-clinical Development
11.7.1.3.6 Manufacturing-Process Optimization
11.7.1.3.7 Other Application
11.7.2 UK
11.7.2.1 Segmentation By End User
11.7.2.1.1 Large Pharmaceutical Companies
11.7.2.1.2 Small and Mid-Size Biotech Firms
11.7.2.1.3 Contract Research Organizations
11.7.2.1.4 Academic and Research Institutes
11.7.2.2 Segmentation By Deployment Mode
11.7.2.2.1 Cloud-Based
11.7.2.2.2 Hybrid
11.7.2.2.3 On-Premise
11.7.2.3 Segmentation By Application
11.7.2.3.1 Clinical-Trial Design and Recruitment
11.7.2.3.2 Drug Discovery and Lead Identification
11.7.2.3.3 Lead Optimization
11.7.2.3.4 Pharmacovigilance and Safety Monitoring
11.7.2.3.5 Pre-clinical Development
11.7.2.3.6 Manufacturing-Process Optimization
11.7.2.3.7 Other Application
11.7.3 France
11.7.3.1 Segmentation By End User
11.7.3.1.1 Large Pharmaceutical Companies
11.7.3.1.2 Small and Mid-Size Biotech Firms
11.7.3.1.3 Contract Research Organizations
11.7.3.1.4 Academic and Research Institutes
11.7.3.2 Segmentation By Deployment Mode
11.7.3.2.1 Cloud-Based
11.7.3.2.2 Hybrid
11.7.3.2.3 On-Premise
11.7.3.3 Segmentation By Application
11.7.3.3.1 Clinical-Trial Design and Recruitment
11.7.3.3.2 Drug Discovery and Lead Identification
11.7.3.3.3 Lead Optimization
11.7.3.3.4 Pharmacovigilance and Safety Monitoring
11.7.3.3.5 Pre-clinical Development
11.7.3.3.6 Manufacturing-Process Optimization
11.7.3.3.7 Other Application
11.7.4 Russia
11.7.4.1 Segmentation By End User
11.7.4.1.1 Large Pharmaceutical Companies
11.7.4.1.2 Small and Mid-Size Biotech Firms
11.7.4.1.3 Contract Research Organizations
11.7.4.1.4 Academic and Research Institutes
11.7.4.2 Segmentation By Deployment Mode
11.7.4.2.1 Cloud-Based
11.7.4.2.2 Hybrid
11.7.4.2.3 On-Premise
11.7.4.3 Segmentation By Application
11.7.4.3.1 Clinical-Trial Design and Recruitment
11.7.4.3.2 Drug Discovery and Lead Identification
11.7.4.3.3 Lead Optimization
11.7.4.3.4 Pharmacovigilance and Safety Monitoring
11.7.4.3.5 Pre-clinical Development
11.7.4.3.6 Manufacturing-Process Optimization
11.7.4.3.7 Other Application
11.7.5 Spain
11.7.5.1 Segmentation By End User
11.7.5.1.1 Large Pharmaceutical Companies
11.7.5.1.2 Small and Mid-Size Biotech Firms
11.7.5.1.3 Contract Research Organizations
11.7.5.1.4 Academic and Research Institutes
11.7.5.2 Segmentation By Deployment Mode
11.7.5.2.1 Cloud-Based
11.7.5.2.2 Hybrid
11.7.5.2.3 On-Premise
11.7.5.3 Segmentation By Application
11.7.5.3.1 Clinical-Trial Design and Recruitment
11.7.5.3.2 Drug Discovery and Lead Identification
11.7.5.3.3 Lead Optimization
11.7.5.3.4 Pharmacovigilance and Safety Monitoring
11.7.5.3.5 Pre-clinical Development
11.7.5.3.6 Manufacturing-Process Optimization
11.7.5.3.7 Other Application
11.7.6 Italy
11.7.6.1 Segmentation By End User
11.7.6.1.1 Large Pharmaceutical Companies
11.7.6.1.2 Small and Mid-Size Biotech Firms
11.7.6.1.3 Contract Research Organizations
11.7.6.1.4 Academic and Research Institutes
11.7.6.2 Segmentation By Deployment Mode
11.7.6.2.1 Cloud-Based
11.7.6.2.2 Hybrid
11.7.6.2.3 On-Premise
11.7.6.3 Segmentation By Application
11.7.6.3.1 Clinical-Trial Design and Recruitment
11.7.6.3.2 Drug Discovery and Lead Identification
11.7.6.3.3 Lead Optimization
11.7.6.3.4 Pharmacovigilance and Safety Monitoring
11.7.6.3.5 Pre-clinical Development
11.7.6.3.6 Manufacturing-Process Optimization
11.7.6.3.7 Other Application
11.7.7 Rest of Europe
11.7.7.1 Segmentation By End User
11.7.7.1.1 Large Pharmaceutical Companies
11.7.7.1.2 Small and Mid-Size Biotech Firms
11.7.7.1.3 Contract Research Organizations
11.7.7.1.4 Academic and Research Institutes
11.7.7.2 Segmentation By Deployment Mode
11.7.7.2.1 Cloud-Based
11.7.7.2.2 Hybrid
11.7.7.2.3 On-Premise
11.7.7.3 Segmentation By Application
11.7.7.3.1 Clinical-Trial Design and Recruitment
11.7.7.3.2 Drug Discovery and Lead Identification
11.7.7.3.3 Lead Optimization
11.7.7.3.4 Pharmacovigilance and Safety Monitoring
11.7.7.3.5 Pre-clinical Development
11.7.7.3.6 Manufacturing-Process Optimization
11.7.7.3.7 Other Application
Chapter 12. Asia Pacific Market
12.1 Market Overview
12.2 Key Factors Impacting Market
12.2.1 Market Drivers
12.2.2 Market Restraints
12.2.3 Market Opportunities
12.2.4 Market Challenges
12.2.5 Market Trends
12.2.6 State of Competition
12.2.7 Market Consolidation
12.2.8 Key Customer Criteria
12.3 Product Life Cycle
12.4 Segmentation By End User
12.4.1 Large Pharmaceutical Companies
12.4.2 Small and Mid-Size Biotech Firms
12.4.3 Contract Research Organizations
12.4.4 Academic and Research Institutes
12.5 Segmentation By Deployment Mode
12.5.1 Cloud-Based
12.5.2 Hybrid
12.5.3 On-Premise
12.6 Segmentation By Application
12.6.1 Clinical-Trial Design and Recruitment
12.6.2 Drug Discovery and Lead Identification
12.6.3 Lead Optimization
12.6.4 Pharmacovigilance and Safety Monitoring
12.6.5 Pre-clinical Development
12.6.6 Manufacturing-Process Optimization
12.6.7 Other Application
12.7 Segmentation By Country
12.7.1 China
12.7.1.1 Segmentation By End User
12.7.1.1.1 Large Pharmaceutical Companies
12.7.1.1.2 Small and Mid-Size Biotech Firms
12.7.1.1.3 Contract Research Organizations
12.7.1.1.4 Academic and Research Institutes
12.7.1.2 Segmentation By Deployment Mode
12.7.1.2.1 Cloud-Based
12.7.1.2.2 Hybrid
12.7.1.2.3 On-Premise
12.7.1.3 Segmentation By Application
12.7.1.3.1 Clinical-Trial Design and Recruitment
12.7.1.3.2 Drug Discovery and Lead Identification
12.7.1.3.3 Lead Optimization
12.7.1.3.4 Pharmacovigilance and Safety Monitoring
12.7.1.3.5 Pre-clinical Development
12.7.1.3.6 Manufacturing-Process Optimization
12.7.1.3.7 Other Application
12.7.2 Japan
12.7.2.1 Segmentation By End User
12.7.2.1.1 Large Pharmaceutical Companies
12.7.2.1.2 Small and Mid-Size Biotech Firms
12.7.2.1.3 Contract Research Organizations
12.7.2.1.4 Academic and Research Institutes
12.7.2.2 Segmentation By Deployment Mode
12.7.2.2.1 Cloud-Based
12.7.2.2.2 Hybrid
12.7.2.2.3 On-Premise
12.7.2.3 Segmentation By Application
12.7.2.3.1 Clinical-Trial Design and Recruitment
12.7.2.3.2 Drug Discovery and Lead Identification
12.7.2.3.3 Lead Optimization
12.7.2.3.4 Pharmacovigilance and Safety Monitoring
12.7.2.3.5 Pre-clinical Development
12.7.2.3.6 Manufacturing-Process Optimization
12.7.2.3.7 Other Application
12.7.3 India
12.7.3.1 Segmentation By End User
12.7.3.1.1 Large Pharmaceutical Companies
12.7.3.1.2 Small and Mid-Size Biotech Firms
12.7.3.1.3 Contract Research Organizations
12.7.3.1.4 Academic and Research Institutes
12.7.3.2 Segmentation By Deployment Mode
12.7.3.2.1 Cloud-Based
12.7.3.2.2 Hybrid
12.7.3.2.3 On-Premise
12.7.3.3 Segmentation By Application
12.7.3.3.1 Clinical-Trial Design and Recruitment
12.7.3.3.2 Drug Discovery and Lead Identification
12.7.3.3.3 Lead Optimization
12.7.3.3.4 Pharmacovigilance and Safety Monitoring
12.7.3.3.5 Pre-clinical Development
12.7.3.3.6 Manufacturing-Process Optimization
12.7.3.3.7 Other Application
12.7.4 South Korea
12.7.4.1 Segmentation By End User
12.7.4.1.1 Large Pharmaceutical Companies
12.7.4.1.2 Small and Mid-Size Biotech Firms
12.7.4.1.3 Contract Research Organizations
12.7.4.1.4 Academic and Research Institutes
12.7.4.2 Segmentation By Deployment Mode
12.7.4.2.1 Cloud-Based
12.7.4.2.2 Hybrid
12.7.4.2.3 On-Premise
12.7.4.3 Segmentation By Application
12.7.4.3.1 Clinical-Trial Design and Recruitment
12.7.4.3.2 Drug Discovery and Lead Identification
12.7.4.3.3 Lead Optimization
12.7.4.3.4 Pharmacovigilance and Safety Monitoring
12.7.4.3.5 Pre-clinical Development
12.7.4.3.6 Manufacturing-Process Optimization
12.7.4.3.7 Other Application
12.7.5 Australia
12.7.5.1 Segmentation By End User
12.7.5.1.1 Large Pharmaceutical Companies
12.7.5.1.2 Small and Mid-Size Biotech Firms
12.7.5.1.3 Contract Research Organizations
12.7.5.1.4 Academic and Research Institutes
12.7.5.2 Segmentation By Deployment Mode
12.7.5.2.1 Cloud-Based
12.7.5.2.2 Hybrid
12.7.5.2.3 On-Premise
12.7.5.3 Segmentation By Application
12.7.5.3.1 Clinical-Trial Design and Recruitment
12.7.5.3.2 Drug Discovery and Lead Identification
12.7.5.3.3 Lead Optimization
12.7.5.3.4 Pharmacovigilance and Safety Monitoring
12.7.5.3.5 Pre-clinical Development
12.7.5.3.6 Manufacturing-Process Optimization
12.7.5.3.7 Other Application
12.7.6 Malaysia
12.7.6.1 Segmentation By End User
12.7.6.1.1 Large Pharmaceutical Companies
12.7.6.1.2 Small and Mid-Size Biotech Firms
12.7.6.1.3 Contract Research Organizations
12.7.6.1.4 Academic and Research Institutes
12.7.6.2 Segmentation By Deployment Mode
12.7.6.2.1 Cloud-Based
12.7.6.2.2 Hybrid
12.7.6.2.3 On-Premise
12.7.6.3 Segmentation By Application
12.7.6.3.1 Clinical-Trial Design and Recruitment
12.7.6.3.2 Drug Discovery and Lead Identification
12.7.6.3.3 Lead Optimization
12.7.6.3.4 Pharmacovigilance and Safety Monitoring
12.7.6.3.5 Pre-clinical Development
12.7.6.3.6 Manufacturing-Process Optimization
12.7.6.3.7 Other Application
12.7.7 Rest of Asia Pacific
12.7.7.1 Segmentation By End User
12.7.7.1.1 Large Pharmaceutical Companies
12.7.7.1.2 Small and Mid-Size Biotech Firms
12.7.7.1.3 Contract Research Organizations
12.7.7.1.4 Academic and Research Institutes
12.7.7.2 Segmentation By Deployment Mode
12.7.7.2.1 Cloud-Based
12.7.7.2.2 Hybrid
12.7.7.2.3 On-Premise
12.7.7.3 Segmentation By Application
12.7.7.3.1 Clinical-Trial Design and Recruitment
12.7.7.3.2 Drug Discovery and Lead Identification
12.7.7.3.3 Lead Optimization
12.7.7.3.4 Pharmacovigilance and Safety Monitoring
12.7.7.3.5 Pre-clinical Development
12.7.7.3.6 Manufacturing-Process Optimization
12.7.7.3.7 Other Application
Chapter 13. LAMEA Market
13.1 Market Overview
13.2 Key Factors Impacting Market
13.2.1 Market Drivers
13.2.2 Market Restraints
13.2.3 Market Opportunities
13.2.4 Market Challenges
13.2.5 Market Trends
13.2.6 State of Competition
13.2.7 Market Consolidation
13.2.8 Key Customer Criteria
13.3 Product Life Cycle
13.4 Segmentation By End User
13.4.1 Large Pharmaceutical Companies
13.4.2 Small and Mid-Size Biotech Firms
13.4.3 Contract Research Organizations
13.4.4 Academic and Research Institutes 13.5 Segmentation By Deployment Mode
13.5.1 Cloud-Based
13.5.2 Hybrid
13.5.3 On-Premise
13.6 Segmentation By Application
13.6.1 Clinical-Trial Design and Recruitment
13.6.2 Drug Discovery and Lead Identification
13.6.3 Lead Optimization
13.6.4 Pharmacovigilance and Safety Monitoring
13.6.5 Pre-clinical Development
13.6.6 Manufacturing-Process Optimization
13.6.7 Other Application
13.7 Segmentation By Country
13.7.1 Brazil
13.7.1.1 Segmentation By End User
13.7.1.1.1 Large Pharmaceutical Companies
13.7.1.1.2 Small and Mid-Size Biotech Firms
13.7.1.1.3 Contract Research Organizations
13.7.1.1.4 Academic and Research Institutes
13.7.1.2 Segmentation By Deployment Mode
13.7.1.2.1 Cloud-Based
13.7.1.2.2 Hybrid
13.7.1.2.3 On-Premise
13.7.1.3 Segmentation By Application
13.7.1.3.1 Clinical-Trial Design and Recruitment
13.7.1.3.2 Drug Discovery and Lead Identification
13.7.1.3.3 Lead Optimization
13.7.1.3.4 Pharmacovigilance and Safety Monitoring
13.7.1.3.5 Pre-clinical Development
13.7.1.3.6 Manufacturing-Process Optimization
13.7.1.3.7 Other Application
13.7.2 Argentina
13.7.2.1 Segmentation By End User
13.7.2.1.1 Large Pharmaceutical Companies
13.7.2.1.2 Small and Mid-Size Biotech Firms
13.7.2.1.3 Contract Research Organizations
13.7.2.1.4 Academic and Research Institutes
13.7.2.2 Segmentation By Deployment Mode
13.7.2.2.1 Cloud-Based
13.7.2.2.2 Hybrid
13.7.2.2.3 On-Premise
13.7.2.3 Segmentation By Application
13.7.2.3.1 Clinical-Trial Design and Recruitment
13.7.2.3.2 Drug Discovery and Lead Identification
13.7.2.3.3 Lead Optimization
13.7.2.3.4 Pharmacovigilance and Safety Monitoring
13.7.2.3.5 Pre-clinical Development
13.7.2.3.6 Manufacturing-Process Optimization
13.7.2.3.7 Other Application
13.7.3 UAE
13.7.3.1 Segmentation By End User
13.7.3.1.1 Large Pharmaceutical Companies
13.7.3.1.2 Small and Mid-Size Biotech Firms
13.7.3.1.3 Contract Research Organizations
13.7.3.1.4 Academic and Research Institutes
13.7.3.2 Segmentation By Deployment Mode
13.7.3.2.1 Cloud-Based
13.7.3.2.2 Hybrid
13.7.3.2.3 On-Premise
13.7.3.3 Segmentation By Application
13.7.3.3.1 Clinical-Trial Design and Recruitment
13.7.3.3.2 Drug Discovery and Lead Identification
13.7.3.3.3 Lead Optimization
13.7.3.3.4 Pharmacovigilance and Safety Monitoring
13.7.3.3.5 Pre-clinical Development
13.7.3.3.6 Manufacturing-Process Optimization
13.7.3.3.7 Other Application
13.7.4 Saudi Arabia
13.7.4.1 Segmentation By End User
13.7.4.1.1 Large Pharmaceutical Companies
13.7.4.1.2 Small and Mid-Size Biotech Firms
13.7.4.1.3 Contract Research Organizations
13.7.4.1.4 Academic and Research Institutes
13.7.4.2 Segmentation By Deployment Mode
13.7.4.2.1 Cloud-Based
13.7.4.2.2 Hybrid
13.7.4.2.3 On-Premise
13.7.4.3 Segmentation By Application
13.7.4.3.1 Clinical-Trial Design and Recruitment
13.7.4.3.2 Drug Discovery and Lead Identification
13.7.4.3.3 Lead Optimization
13.7.4.3.4 Pharmacovigilance and Safety Monitoring
13.7.4.3.5 Pre-clinical Development
13.7.4.3.6 Manufacturing-Process Optimization
13.7.4.3.7 Other Application
13.7.5 South Africa
13.7.5.1 Segmentation By End User
13.7.5.1.1 Large Pharmaceutical Companies
13.7.5.1.2 Small and Mid-Size Biotech Firms
13.7.5.1.3 Contract Research Organizations
13.7.5.1.4 Academic and Research Institutes
13.7.5.2 Segmentation By Deployment Mode
13.7.5.2.1 Cloud-Based
13.7.5.2.2 Hybrid
13.7.5.2.3 On-Premise
13.7.5.3 Segmentation By Application
13.7.5.3.1 Clinical-Trial Design and Recruitment
13.7.5.3.2 Drug Discovery and Lead Identification
13.7.5.3.3 Lead Optimization
13.7.5.3.4 Pharmacovigilance and Safety Monitoring
13.7.5.3.5 Pre-clinical Development
13.7.5.3.6 Manufacturing-Process Optimization
13.7.5.3.7 Other Application
13.7.6 Nigeria
13.7.6.1 Segmentation By End User
13.7.6.1.1 Large Pharmaceutical Companies
13.7.6.1.2 Small and Mid-Size Biotech Firms
13.7.6.1.3 Contract Research Organizations
13.7.6.1.4 Academic and Research Institutes
13.7.6.2 Segmentation By Deployment Mode
13.7.6.2.1 Cloud-Based
13.7.6.2.2 Hybrid
13.7.6.2.3 On-Premise
13.7.6.3 Segmentation By Application
13.7.6.3.1 Clinical-Trial Design and Recruitment
13.7.6.3.2 Drug Discovery and Lead Identification
13.7.6.3.3 Lead Optimization
13.7.6.3.4 Pharmacovigilance and Safety Monitoring
13.7.6.3.5 Pre-clinical Development
13.7.6.3.6 Manufacturing-Process Optimization
13.7.6.3.7 Other Application
13.7.7 Rest of LAMEA
13.7.7.1 Segmentation By End User
13.7.7.1.1 Large Pharmaceutical Companies
13.7.7.1.2 Small and Mid-Size Biotech Firms
13.7.7.1.3 Contract Research Organizations
13.7.7.1.4 Academic and Research Institutes
13.7.7.2 Segmentation By Deployment Mode
13.7.7.2.1 Cloud-Based
13.7.7.2.2 Hybrid
13.7.7.2.3 On-Premise
13.7.7.3 Segmentation By Application
13.7.7.3.1 Clinical-Trial Design and Recruitment
13.7.7.3.2 Drug Discovery and Lead Identification
13.7.7.3.3 Lead Optimization
13.7.7.3.4 Pharmacovigilance and Safety Monitoring
13.7.7.3.5 Pre-clinical Development
13.7.7.3.6 Manufacturing-Process Optimization
13.7.7.3.7 Other Application
Chapter 14. Company Snapshot
14.1 InSilico Medicine
14.1.1 Business Overview
14.1.2 Key Information
14.1.3 Company Focus
14.1.4 Strategic Insights
14.1.5 Strategy Deployed
14.1.6 Product & Service Portfolio
14.1.7 Capability Overview
14.1.8 Technology & Innovation Focus
14.1.9 Customers / End Users
14.1.10 Competitive Positioning
14.1.11 Key Differentiators
14.1.12 Portfolio Matrix
14.1.13 SWOT Analysis
14.1.14 Future Outlook
14.2 Numerion Labs, Inc.
14.2.1 Business Overview
14.2.2 Key Information
14.2.3 Company Focus
14.2.4 Strategic Insights
14.2.5 Strategy Deployed
14.2.6 Product & Service Portfolio
14.2.7 Capability Overview
14.2.8 Technology & Innovation Focus
14.2.9 Customers / End Users
14.2.10 Competitive Positioning
14.2.11 Key Differentiators
14.2.12 Portfolio Matrix
14.2.13 SWOT Analysis
14.2.14 Future Outlook
14.3 BenevolentAI Group
14.3.1 Business Overview
14.3.2 Key Information
14.3.3 Company Focus
14.3.4 Strategic Insights
14.3.5 Strategy Deployed
14.3.6 Product & Service Portfolio
14.3.7 Capability Overview
14.3.8 Technology & Innovation Focus
14.3.9 Customers / End Users
14.3.10 Competitive Positioning
14.3.11 Key Differentiators
14.3.12 Portfolio Matrix
14.3.13 SWOT Analysis
14.3.14 Future Outlook
14.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
14.4.1 Business Overview
14.4.2 Key Information
14.4.3 Company Focus
14.4.4 Strategic Insights
14.4.5 Strategy Deployed
14.4.6 Product & Service Portfolio
14.4.7 Capability Overview
14.4.8 Technology & Innovation Focus
14.4.9 Customers / End Users
14.4.10 Competitive Positioning
14.4.11 Key Differentiators
14.4.12 Portfolio Matrix
14.4.13 SWOT Analysis
14.4.14 Future Outlook
14.5 Recursion Pharmaceuticals, Inc.
14.5.1 Business Overview
14.5.2 Key Information
14.5.3 Company Focus
14.5.4 Strategic Insights
14.5.5 Strategy Deployed
14.5.6 Product & Service Portfolio
14.5.7 Capability Overview
14.5.8 Technology & Innovation Focus
14.5.9 Customers / End Users
14.5.10 Competitive Positioning
14.5.11 Key Differentiators
14.5.12 Portfolio Matrix
14.5.13 SWOT Analysis
14.5.14 Future Outlook
14.6 Deep Genomics Incorporated
14.6.1 Business Overview
14.6.2 Key Information
14.6.3 Company Focus
14.6.4 Strategic Insights
14.6.5 Strategy Deployed
14.6.6 Product & Service Portfolio
14.6.7 Capability Overview
14.6.8 Technology & Innovation Focus
14.6.9 Customers / End Users
14.6.10 Competitive Positioning
14.6.11 Key Differentiators
14.6.12 Portfolio Matrix
14.6.13 SWOT Analysis
14.6.14 Future Outlook
14.7 Schrödinger, LLC
14.7.1 Business Overview
14.7.2 Key Information
14.7.3 Company Focus
14.7.4 Strategic Insights
14.7.5 Strategy Deployed
14.7.6 Product & Service Portfolio
14.7.7 Capability Overview
14.7.8 Technology & Innovation Focus
14.7.9 Customers / End Users
14.7.10 Competitive Positioning
14.7.11 Key Differentiators
14.7.12 Portfolio Matrix
14.7.13 SWOT Analysis 14.7.14 Future Outlook
14.8 Owkin Inc.
14.8.1 Business Overview
14.8.2 Key Information
14.8.3 Company Focus
14.8.4 Strategic Insights
14.8.5 Strategy Deployed
14.8.6 Product & Service Portfolio
14.8.7 Capability Overview
14.8.8 Technology & Innovation Focus
14.8.9 Customers / End Users
14.8.10 Competitive Positioning
14.8.11 Key Differentiators
14.8.12 Portfolio Matrix
14.8.13 SWOT Analysis
14.8.14 Future Outlook
14.9 PeptiDream Inc.
14.9.1 Business Overview
14.9.2 Key Information
14.9.3 Company Focus
14.9.4 Strategic Insights
14.9.5 Strategy Deployed
14.9.6 Product & Service Portfolio
14.9.7 Capability Overview
14.9.8 Technology & Innovation Focus
14.9.9 Customers / End Users
14.9.10 Competitive Positioning
14.9.11 Key Differentiators
14.9.12 Portfolio Matrix
14.9.13 SWOT Analysis
14.9.14 Future Outlook
14.10 Healx Limited
14.10.1 Business Overview
14.10.2 Key Information
14.10.3 Company Focus
14.10.4 Strategic Insights
14.10.5 Strategy Deployed
14.10.6 Product & Service Portfolio
14.10.7 Capability Overview
14.10.8 Technology & Innovation Focus
14.10.9 Customers / End Users
14.10.10 Competitive Positioning
14.10.11 Key Differentiators
14.10.12 Portfolio Matrix
14.10.13 SWOT Analysis
14.10.14 Future Outlook
Chapter 15. Winning Imperatives of Agentic AI In Pharmaceuticals Market
Unique Offerings 
